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Summary DBA2 mice were inoculated i.p. with 105 L1210 cells. Animals subsequently treated with
daunomycin (single i.p. dose, 0.25-5.0mgkg-1) all died. The maximum increase in mean survival time
observed was 135%. Animals treated with N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers
conjugated to daunomycin (DNM) showed a significant increase in mean survival time when the polymer-
drug linkage was biodegradable (i.e., Gly-Phe-Leu-Gly). Such treatment also produced a number of long term
survivors (>50 days). In contrast, HPMA copolymer conjugated to DNM via a non-degradable linkage (Gly-
Gly) produced no increase in survival time relative to untreated control animals. The effect observed with
biodegradable HPMA copolymer-DNM conjugates was dependent on the concentration of conjugated drug
administered (optimum >5mgkg-1); the frequency of administration (multiple doses were more effective
than single); the timing of administration (single doses given on days 1 and 3 were most effective); and the
site of tumour inoculation and route of drug administration. Biodegradable HPMA copolymer-DNM
conjugates administered i.p. were active against L1210 inoculated s.c. at higher doses than required to curb a
peritoneal tumour. Under certain experimental conditions polymer-DNM conjugates containing fucosylamine
or galactosamine proved more active than conjugates without the carbohydrate moeity. The mechanism of
drug-conjugate action in vivo is at present unclear. Radioiodination of polymer showed -75% of polymer-
drug conjugate to be excreted 24h after i.p. administration. Synthesis of HPMA conjugates containing
[3H]DNM showed that polymer containing Gly-Gly-[3H]DNM was excreted (60% of radioactivity in the
urine, 24h) in macromolecular form. In contrast polymer containing Gly-Phe-Leu-Gly-[3H]DNM was largely
excreted in the form of low molecular weight species.
Use of tailor-made polymeric drug-carriers to achieve
tumour-specific drug-targeting is receiving increasing interest
(Duncan & Kopecek, 1984). Unlike liposomes and micro-
particles, whose distribution within the body is severely
limited, macromolecular drug-carriers can move from one
body compartment to another and target to specific organs
following different routes of administration (Duncan et al.,
1986; Duncan, 1987; Seymour et al., 1987a). A number of
different macromolecules have been proposed as carriers of
antitumour agents: dextran-mitomycin C (Koijma et al., 1980;
Takakura et al., 1984), poly-L-aspartic acid-daunomycin
(Zunino et al., 1984), poly-L-lysine-methotrexate (Ryser &
Shen, 1980; Chu & Howell, 1981), bovine or human serum
albumin-methotrexate (Chu et al., 1981; Garnett et al.,
1985), DNA-daunomycin (Deprez-de Campeneere & Trouet,
1980), human serum albumin-daunomycin (Trouet et al.,
1982). Many of these drug conjugates are potent cytotoxic
agents in vitro and in certain cases have been used to
circumvent drug resistance (Ryser & Shen, 1980). Some also
display increased therapeutic efficiency in vivo (Trouet et al.,
1982).
Soluble synthetic copolymers of N-(2-hydroxypropyl)-
methacrylamide (HPMA) developed as drug-carriers have
previously been described (Kopecek & Duncan, 1987a;
Kopecek et al., 1985a). They can be synthesized to
include peptide side-chains for drug attachment and release
(Duncan et al., 1983; Rejmanova et al., 1983) and also for
attachment of targeting moeties, e.g., carbohydrates (Duncan
et al., 1986) or antibodies (Rihova & Kopecek, 1985). Such
copolymers containing daunomycin (DNM) and puromycin
were shown to be toxic to mouse and human leukaemia
grown in vitro (Duncan et al., 1987) and degree of toxicity
found to correlate with biodegradability of the drug-
polymer linkage, and to the presence of residues known to
promote cellular uptake. Similarly, melphalan-HPMA co-
polymers were shown to be toxic (although less so) to
L1210 in vitro (Ulbrich et al., 1987). In addition, HPMA
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copolymers containing DNM and anti 0 antibodies show
antibody-dependent toxicity to T lymphocytes in vitro and
in vivo (kihova' et al., 1986).
To evaluate their potential for clinical use HPMA
copolymer-DNM conjugates have been tested against L1210
leukaemia in DBA2 mice. Mice bearing L1210 (i.p. or s.c.)
were treated intraperitoneally with free DNM or HPMA
copolymer-DNM conjugates (chemical structures shown in
Figure 1 and Table I). Animal weight and survival-time was
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Figure 1 Chemical structure of N-(2-hydroxypropyl) metha-
crylamide-daunomycin conjugates.
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monitored. Drug conjugates containing non-degradable
drug-polymer linkages (Gly-Gly) or biodegradable linkages
(Gly-Phe-Leu-Gly) were synthesized and certain polymer
conjugates contained in addition carbohydrate residues.
Conjugates containing fucose were prepared as L1210 cells
are known to possess a cell surface receptor which recognises
fucose (Monsigny et al., 1984). In addition we have shown
that incorporation of galactose into HPMA copolymers
effectively targets the polymer to hepatocytes in vivo
(Duncan et al., 1986) and human hepatoma, HepG2 in vitro
(O'Hare et al., in preparation). Therefore the antitumour
activity of an HPMA copolymer containing galactosamine
was also investigated.
Although this study represents the first investigation of
pharmacological activity of HPMA copolymer-DNM, it was
also considered important to investigate the body
distribution of polymer-drug for comparison with that of
free drug. Also to investigate the degradation of the
polymer-drug conjugates in vivo. Previous measurement of
conjugate stability had been made in vitro. The body
distribution of radiolabelled drug ([3H]DNM) and radio-
labelled polymeric carrier (125I-labelled or [3H]DNM was
followed over 7 days after i.p. administration.
Materials and methods
Chemicals
l-Aminopropan-2-ol, methacryloylchloride, glycylglycine,
dimethylsulphoxide (DMSO) and 4-nitrophenol were from
FLUKA AG, Buchs, Switzerland. Glycylphenylalanine,
leucylglycine, phenylalanylleucine, tyrosinamide, L-
fucosylamine, D-galactosamine and daunomycin were from
Sigma Chemical Co., Poole, Dorset, U.K. [I251]Iodide
(preparation IMS.30) was from Amersham International,
UK and [3H]DNM (preparation NET-582; 2.2Cimmol-1)
was from New England Nuclear, Boston, USA. Liquiscint
was from National Diagnostics, Somerville, New Jersey,
USA.
Preparation ofpolymers
HPMA copolymer-DNM conjugates were prepared as
described previously (Kopecek et al., 1985b; Duncan et al.,
1987). Briefly, the conjugates were synthesized using a two-
step procedure. Polymeric precursors (Table I) were prepared
by radical precipitation copolymerization of HPMA, MA-
TyrNH2 (N-methacryolyltyrosinamide) and the respective
N-methacryloyloligopeptide p-nitrophenyl (ONp) ester
(Kopecek, 1977; Kopecek & Rejmanovia, 1979). DNM,
galactosamine and fucosylamine were subsequently bound to
these polymeric precursors by consecutive aminolysis
(Kopecek et al., 1985b; Duncan et al., 1987). The structure
and chemical characteristics of the polymers used in this
study are shown in Figure 1 and Table I. All HPMA
copolymer-DNM conjugates were purified by dissolving the
polymer in methanol and applying to a Sephadex LH-20
column (2 x 95 cm, eluant methanol). The high molecular
weight fraction was isolated and the methanol evaporated.
Polymers were subsequently dissolved in water and freeze-
dried. All contained <0.1 relative % of free DNM
compared with the amount of bound DNM.
The HPMA copolymers containing [3H]DNM (samples 7
and 8) were prepared as follows:
Table I Chemical characteristics of the HPMA copolymers
Polymer Precursor Side-chain Substitution Drug content
code no. used structure (mol %) (wt %)
1pTyrNH2 -
1GlyGlyONp 4 -
2 _ p TyrNH2 ,%,I -
'GlyPheLeuGlyONp 8
Polymers
3 1 p.-TyrNH2 1-1 7 -GlyGlyDNMa 3
4 2 p_-TyrNH2 1 9 'GlyPheLeuGlyDNM 3
7TyrNH2 1
5 2 P-GlyPheLeuGlyDNM 2 6.5
GlyPheLeuGlyfucosylamineb 2.5
TyrNH2 1
6 2 PKGlyPheLeuGlyDNM 3 7
NGlyPheLeuGlygalactosaminec 4
Polymers containing [3H]DNM
/TyrNH2 - 1
7 2 P-GlyPheLeuGly[3H]DNM 3 7
GlyPheLeuGlygalactosamine 4
8 1 p..TyrNH2-3 7 "-GlyGly[3HJDNM 3
All copolymers contained TyrNH2, 1 mol% to permit radiolabelling. aM, of
polymeric precursors 1 and 2 were 21,000 and 17,000, respectively; M,/Mn was 1.3 in
both cases. These values were determined after aminolysis of the polymeric precursors
with 1-aminopropan-2-ol using Sepharose 4B/6B (1:1) column chromatography
(1.6 x 90cm). A 0.05M TRIS buffer containing 0.5 MNaCl (pH8.0) was used. The
column was calibrated using fractions ofpoly(HPMA); "The amount of bound DNM
was estimated spectrophotometrically (e480 =9.8 x 103 in H20); cFucosylamine
content was extrapolated from the p-nitrophenol release during aminolysis of the
polymeric precursor with fucosylamine; dGalactosamine content was estimated as
previously described (Plummer et al., 1976; Cheng & Boat, 1978).ACTIVITY OF HPMA-DAUNOMYCIN CONJUGATES IN VIVO 149
Polymer 7 One hundred mg of polymeric precursor 2
(Table I) (4.4 x 10-5 mol ONp groups) was dissolved in
dimethylsulphoxide (DMSO, 0.4ml) and [3H]DNM added
(20,u1 of a DMSO solution containing 50pg/210pCi). After
stirring for 10min excess non-radioactive DNM.HC1 was
added (12.4mg, 2.2x 10-5mol) followed by addition of
triethylamine (3.1 1l, 2.2x 10-5mol). The reaction mixture
was stirred for a further 2h before addition (in DMSO) of
galactosamine.HCI (13mg, 6.0 x 10 5mol) and triethylamine
(8.4 1l, 6.0x1O-5mol). The reaction mixture was then left
stirring overnight. The polymer was precipitated in acetone,
as previously described (Duncan et al., 1987).
Polymer 8 One hundred mg of polymeric precursor 1
(Table I) (2.6 x 10- 5mol ONp groups) was dissolved in
DMSO (0.4ml) and 20,u1 of a [3H]DNM solution added.
Likewise, after stirring for 10min, excess non-radiolabelled
DNM.HC1 was added (13.5mg, 2.4x 10-5mol) together
with trimethylamine/3.3p1, 2.4x 10-5mol) both in DMSO
(0.1 ml). The reaction mixture was left overnight before
precipitation in acetone, as described above.
The specific activity of polymers 7 and 8 was
- 1.0juCimg 1 polymer.
Evaluation against L1210 leukaemia in vivo
Evaluation of DNM and HPMA copolymer-DNM con-
jugates was carried out essentially as described in the
National Cancer Institute Protocol (Geran et al., 1972).
DBA2 mice (males 9-12wks, 20-30g) were inoculated i.p. or
s.c. with 105 viable L1210 cells. Cell numbers were assessed
using a haemocytometer slide, and viability using Trypan
blue exclusion as the criterion for cellular integrity. The
animals were weighed daily, and observed twice a day for
signs of tumour progression. The survival time was
monitored.
DNM or HPMA copolymer-DNM conjugates were
dissolved in sterile phosphate-buffered saline. The stated
doses (mgkg-1) represent the dose of free or conjugated
drug (-5-10wt% of the conjugate) administered in -0.5ml
on day 1, 2, 3, 5 or 8 after tumour inoculation. In certain
experiments single doses were given; others involved multiple
dosing. The precise dosing schedule is indicated for each
experiment. Results are expressed as the mean survival time
of those animals dying within the experimental period, and
the number of animals in each group surviving the
experiment is also given. The statistical significance of the
difference in survival time between control (no treatment)
and treated groups was estimated using a Student's t test for
small samples.
Body distribution of 125I-labelled HPMA copolymers
HPMA copolymers containing methacryloyltyrosinamide
(samples 3-6) were radioiodinated (121I) using the
Chloramine T method, as described previously (Duncan et
al., 1984). The specific activity of the resultant preparations
was -l51Cimg-1, and they contained <5% free
[125I]iodide. DBA2 mice under ether anaesthetic, were
injected i.p. with 125I-labelled HPMA copolymer (0.1 ml,
200pg of copolymer) and the body distribution of radio-
activity examined after 1 h, Sh, 24h and 7 days. Animals
were maintained in metabolic cages and urine and faeces
collected throughout.
At the end of all experimental periods animals were
subjected to ether anaesthetic. To assess the radioactivity
remaining in the peritoneal cavity, animals were injected i.p.
with saline (2ml). After agitation of the abdomen this
solution was retrieved (as far as possible) using a Pasteur
pipette and assayed for radioactivity. A 50I1 blood sample
was taken by puncturing the heart and then dispersed in I M
NaOH (I ml) and assayed for radioactivity. All the major
organs were removed and washed in ice cold saline: liver,
lungs, kidneys, spleen, stomach, intestines, colon and rectum.
Organs were routinely homogenized to a known volume in
water or, in the case of stomach and other tissues from the
gastrointestinal tract, dissolved in a known volume of 1 M
NaOH. All samples, including urine and faeces (dispersed to
a known volume) were assayed for radioactivity. The total
radioactivity recovered from each organ, urine, faeces and
blood (assuming a blood volume equivalent to 5.77ml/100g
of mouse (Dreyer & Ray, 1910) was calculated and these
values summed to give the total radioactivity recovered from
the body at each time. This value was also expressed as a
percentage of the dose administered.
Body distribution of[3H]DNM conjugates
Body distributions were assessed essentially as described
above. Under ether anaesthetic, DBA2 mice were injected
intraperitoneally with [3H]DNM (0.1 ml, - 2.5 ,ug), sample 7
(0.2ml, .260yg conjugate), or sample 8 (0.2ml, -260,ug
conjugate). The animals were allowed to recover and
maintained in metabolic cages for 1, 5 or 24h. At the end of
the experimental period, a 50,u1 blood sample (dispersed in
1 M NaOH, 1.0ml) was taken, the animal sacrificed and
organs (as described above) removed. All samples were
prepared as described previously and assayed for radio-
activity. Homogenates (0.5ml) and samples of urine, faeces
and blood (0.5ml) were mixed with 4.5ml of a complete
scintillant cocktail (Liquiscint) and counted for 10min. Each
sample was subsequently spiked with a [3H] standard
(-20,000cpm added to each vial) and re-counted in order to
assess the extent of quenching in each sample. The measured
radioactivity in each sample was then corrected for the
degree of quenching and the body distribution expressed in
the same way as described for 125I-labelled polymers.
Analysis ofradioactivity recoveredfrom urine andperitoneal
washings using Sephadex G-25 chromatography
Following certain body distribution experiments radioactivity
recovered in the urine or peritoneal washings was subjected
to Sephadex G-25 chromatography. Samples were applied to
a disposable PD-10 column (Pharmacia) and eluted with
0.05M sodium acetate (0.5ml fractions). The columns were
calibrated with blue-Dextran, 125J- and [3H]DNM.
Results
DBA2 mice inoculated i.p. with 105 L1210 cells died
consistently after 14-17 days (Figures 2-5; Tables II-IV).
Over the experimental period these animals showed a steady
weight gain (Figure 2) up to 140% of the starting weight.
-a
0.
Time (days)
Figure 2 Effect of free daunomycin on the weight, and survival,
of DBA2 mice inoculated i.p. with 105 L1210 cells. The L1210
cells were given on day 0 and DNM administered i.p. on day 1
at doses of 0 (0), 0.25 (A), 0.5 (-), 0.75 (0), 2 (El) or
5mgkg-' (AL). All animals died, and the time (days) when the
last member of the group died is indicated.150 R. DUNCAN et al.
Table II Survival of DBA2 mice bearing i.p. L1210 leukaemia following i.p.
treatment with DNM
Dose Mean survival Long term
Treatment (mgkg-1) Day ofdeath (±s.e.) survivors
Nonea - 15, 15, 16, 16, 17 15.8+0.4 0/5
DNM 0.25 14, 15, 15, 20, 22 17.2+1.6NS 0/5
DNM 0.5 17, 21, 21, 22, 27 21.6+1.6* 0/5
DNM 0.75 19, 19, 21, 22, 22 20.6+0.7* 0/5
DNM 2.0 15, 16, 19, 19, 23 18.4+1.4NS 0/5
DNM 5.0 10, 10, 10, 13, 13 11.2+0.7** 0/5
'DNM was administered on day 1 after i.p. inoculation of 105 L1210 cells.
*P<0.01; **P<0.001.
Administration of a single, i.p. dose of free DNM (0.25-
5.0mgkg-1) had a dose-dependent effect indicated by
marked weight change (Figure 2). A dose of 2mgkg-1
produced slight weight loss, 5mgkg-' caused rapid weight
loss (to 76% of the starting weight), whereas lower doses of
drug, 0.75, 0.5 and 0.25mgkg-1, did not prevent tumour-
associated weight gain. Although certain doses did produce a
significant increase in the mean survival time (Table II), the
maximum increase was limited to - 135% of that recorded
for the untreated control group.
Initial experiments carried out to evaluate the effectiveness
of HPMA copolymer-DNM conjugates used a treatment
regime comprising three i.p. doses of conjugate given on
days 1, 2 and 3 after i.p. inoculation of 105 L1210 cells.
Survival times (Figure 3 and Table III) and the weight
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changes of the animals in each group (Figure. 4) are shown.
Free DNM (3 doses) at a daily dose of 2 or 5mgkg-1 was
unable to prolong survival time; indeed the higher dose
significantly decreased life expectancy (Figure 3).
Administration of HPMA copolymer-DNM conjugates
affected the survival time of L1210-bearing mice, in a
manner related to the conjugate composition (Table III). The
non-degradable P-Gly-Gly-DNM conjugate (sample 3)
caused no significant increase in lifespan. In contrast the
biodegradable conjugates containing P-Gly-Phe-Leu-Gly-
DNM (samples 4, 5 and 6), produced an increase in the
mean lifespan (of those animals that died during the course
of the experiment) and, in certain experiments, a number of
animals survived.
Weight changes observed in mice treated with either free,
or conjugated, DNM were consistent with their measured
survival-times (Figure 4). The animals treated with free
DNM (3 doses in this case) all lost weight and died early
in the experiment. Both those treated with the non-
biodegradable conjugate (sample 3), and the untreated
control group, gained weight rapidly, and also showed visual
evidence of their rapidly growing peritoneal ascites. How-
ever, animals treated with biodegradable HPMA copolymer-
DNM conjugates (with or without L-fucosylamine) showed
little or no weight-change. Those animals dying within the
experimental period did eventually succumb to the tumour.
Effect of the timing, and size of the dose administered is
shown in Table IV. A single dose of P-Gly-Phe-Leu-Gly-
DNM (sample 4) given on day 1 or day 3 was sufficient to
increase the mean survival-time considerably. However, when
administered on day S or day 8 a single dose of sample 4
produced no significant increase in mean survival time.
Administration of sample 4 at different doses on day 1 or
day 3 (Table IV, experiments 1 and 3) showed doses in the
range 5.0-20mgkg-1 to be similarly effective (with a slight
increase in activity as the dose administered increased).
Time (days)
Figure 4 Effect of free daunomycin and HPMA copolymer-
daunomycin administered i.p. on the weight of DBA2 mice
inoculated L1210 cells on day 0. Drug, or drug conjugate, was
administered i.p. on days 1, 2 and 3; DNM 2mgkg-l (0);
DNM 5mgkg-1 (0); conjugate 3 (-); conjugate 4 (A) or
conjugate 5 (A). Untreated control animals are also shown ([1)
and all conjugates were given at a dose of Smgkg-1 in respect
of the contained DNM.
Table IV Survival of DBA2 mice bearing i.p. L1210 leukaemia after i.p. treatment with DNM or HPMA copolymer-DNM. Effect of dose
and timing of administration
Treatment
Mean
Sample Dose Day of survival Long term
Experiment no. Polymer side-chain (mgkg-1) admin. Day ofdeath (±s.e.) survivors
1. Administration on days I or 3
None - - 15, 15, 15, 15, 15, 16, 16 16.4+0.6 0/10
17, 20, 20
DNM 5.0 1 15, 15, 16, 16, 23 17.0+ 1.5NS 0/5
4 P-Gly-Phe-Leu-Gly-DNM 2.5 1 15, 17, 19, 20, 20, 20, 20, 22 19.1 +0.8* 0/8
4 P-Gly-Phe-Leu-Gly-DNM 5.0 1 21, 24, 24, 28, 29, 30, 39 27.8+2.3*** 1/8
4 P-Gly-Phe-Leu-Gly-DNM 7.5 1 21, 23, 24, 24, 26, 27, 43 26.8+2.8*** 1/8
4 P-Gly-Phe-Leu-Gly-DNM 5.0 3 21, 22, 25, 28, 31, 32 26.5+ 1.9*** 0/6
4 P-Gly-Phe-Leu-Gly-DNM 7.5 3 27, 28, 29, 35, 38, 38 32.5+2.1*** 2/8
5 p,Gly-Phe-Leu-GlyDNM i 7.5 1 25, 26, 26, 32, 32, 34 29.2+1.6*** 0/6
5 P.--Gly-Phe-Leu-Gly-DNM 7.5 3 28, 31, 33 30.7+1.5*** 4/6
2. Administration on days 1, 5 or 8
None - - 15, 15, 17, 18, 18 16.6+0.7 0/5
DNM - 2.0 1 19, 19, 22, 22, 23 21.0+0.8** 0/5
HPMA 20.0 1 12, 17, 18, 18, 23 17.6+1.7NS 0/5 DNM 2.0
4 P-Gly-Phe-Leu-Gly-DNM 5.0 1 19, 20, 22, 22, 25 21.6+ 1.0** 0/5
4 P-Gly-Phe-Leu-Gly-DNM 5.0 5 15, 17, 17, 18, 18 17.0+0.5NS 0/5
4 P-Gly-Phe-Leu-Gly-DNM 5.0 8 17, 17, 18, 18, 18 17.6+0.2NS 0/5
3. Administration on day 3
None - 16, 17, 17, 17, 17 16.8+0.2 0/5
4 P-Gly-Phe-Leu-Gly-DNM 5.0 3 20, 24, 25, 34 25.8+3.0* 1/5
4 P-Gly-Phe-Leu-Gly-DNM 7.5 3 16, 19, 19, 23, 25 20.4+ 1.6* 0/5
4 P-Gly-Phe-Leu-Gly-DNM 10.0 3 17, 22, 26 21.6+2.6* 2/5
4 P-Gly-Phe-Leu-Gly-DNM 15.0 3 20, 23, 24, 26, 33 25.2+2.2*** 0/5
4 P-Gly-Phe-Leu-Gly-DNM 20.0 3 20, 21, 23, 25, 26 23.0+ 1.1*** 0/5
*P<0.05; **P<0.01; ***P<0.001.
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In contrast the lower dose of 2.5mgkg1 was totally
ineffective.
Sample 5 (containing L-fucosylamine) was not obviously
more effective than sample 4 when given on day 1. However,
when administered on day 3, sample 5 appeared more active
producing a larger number of long term survivors.
Administration of polymer-bound DNM up to doses of
20mgkg-1 produced no visual signs of toxicity and
measured animal weights in these experiments did not show
any signs of sudden weight loss such as those associated with
acute DNM toxicity (cf. Figures 2 & 5).
Untreated animals inoculated s.c. with L1210 died with a
mean survival time of 16-20 days (Table V). Again free
DNM did not improve this situation. Although, polymer-
bound DNM (Sample 4) administered i.p. was not effective
at 5mgkg- I (a concentration shown previously to act
against i.p. tumour), concentrations of 10-20mgkg-1
significantly increased the mean survival time and also give
rise to long term survivors.
251I-Labelled samples 4 and 5, administered i.p. showed
different body distributions during the first 24h (Figures 5 &
6). Both left the peritoneal cavity rapidly, 50% leaving
within the first hour. However, the polymer containing L-
fucosylamine residues (sample 5) seemed to pass more
readily from the bloodstream into the kidney. At 24h both
polymers showed an almost identical body distribution, with
76% of radioactivity recovered from sample 5 in kidney or
urine, and likewise 65% of sample 4 (Figure 7). Sephadex
G-25 chromatography of urine collected during the 24h
following i.p. administration of 1251-labelled sample 5
showed >60% of radioactivity in urine to be in macro-
molecular form (Figure 8). After 7 days almost all of the
administered sample 4 and 5 had been excreted.
125I-Labelling of tyrosinamide residues in the polymer
backbone is limited as it permits only tracing of the
polymeric carrier. Studies were therefore carried out using
[3H]DNM and HPMA copolymers containing [3H]DNM to
monitor drug fate, both in free and conjugated form. After
i.p. administration, body distributions were assessed (1, 5
and 24h) and results obtained are shown in Table VI. Free
[3H]DNM showed substantial association with the intestine
(49% of the radioactivity recovered after the first hour), and
subsequently radioactivity appeared in the faeces. Both
[3H]DNM and sample 7 showed some evidence of liver
association, and this was particularly noticeable in the case
of D-galactosamine-containing conjugate (sample 7), 32% of
the radioactivity recovered being detected in the liver after
1 h and (29%) after 5h. Sample 8 did not accumulate to any
significant extent in the liver.
It is interesting to compare the rate of excretion of free
Table V Survival of DBA2 mice bearing s.c. L1210 leukaemia following i.p. treatment with DNM or HPMA copolymer-
DNM
Dose Mean survival time Long term Increase in mean
Treatmenta (mgkg 1) Day ofdeath (±s.e.) survivors survival time (%)
None - 16, 19, 19, 23, 23, 23 20.5+1.1 0/6
(Expt. 2) - 16, 16, 16, 16, 16 16.0+0 0/5 -
DNM 5 9, 9, 9, 10, 24 12.2+2.9* 0/5 60
Sample 4 5 20, 23, 24, 24, 35 25.2+2.5NS 0/5 123
(P-Gly-Phe-Leu-Gly-DNM)
(Expt. 2) 5 19, 20, 20, 22, 25 21.2+1.1NS 0/5 133
10 24, 25, 27, 37 28.3+3.0* 1/5 138
15 25, 32, 49 35.3+7.1* 2/5 172
20 22, 22 22 2/4 107
'DNM and HPMA copolymer-DNM were administered on days 1, 2 and 3 after tumour inoculation; *P<0.05.
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Figure 5 Effect of dose on animal weight after i.p. administration ofP-Gly-Phe-Leu-Gly-DNM to DBA2 mice bearing i.p. L1210.
L1210 cells were administered i.p. on day 0 and HPMA copolymer-DNM on day 3; no treatment ( 0); 5 (O---0);
10 (0 0); 15 (--- 0) and 20mgkg1 (M- *). The percent weight change is shown and also the day of death of the last
surviving animal in each group.ACTIVITY OF HPMA-DAUNOMYCIN CONJUGATES IN VIVO
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Figure 6 Body distribution of radioactivity after i.p. injection of
125I-labelled copolymer 4 to DBA2 mice. The radioactivity
recovered in each organ was expressed as a percentage of the
total radioactivity recovered from the animal (mean+s.e. of 3
animals). Radioactivity recovered from the peritoneal cavity (0-
0), urine and faeces (U U), blood (0 0), kidney
(A A), gastrointestinal tract (l---O) and liver (A---A)
is shown.
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Figure 8 Sephadex G-25 elution of mouse urine collected 24h
after i.p. administration of 1251-labelled copolymer 5 procedure is
given in Materials and methods. Elution of dextran blue (V0) and
1251 is shown.
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Figure 7 Body distribution of radioactivity after i.p. injection of
125I-labelled copolymer 5. The radioactivity recovered in each
organ was expressed as a percentage of the total radioactivity
recovered from the animal (mean+s.e. of 3 animals). Radio-
activity recovered in the various organs is indicated according to
the key shown in the legend to Figure 6.
and conjugated [3H]DNM. For free [3H]DNM, 46% of the
radioactivity recovered after 24h was in the urine and faeces.
This compares with 72% of sample 7 and 73% of sample 8.
If these results are related to the dose administered, only
10.2% of free [3H]DNM is excreted within 24h compared
with 29% and 35% of samples 7 and 8 respectively.
Sephadex G-25 chromatography of peritoneal samples 1h
after administration showed two peaks corresponding to
either low or high molecular weight material and,
representing [3H]DNM and conjugate respectively (Table
VII).
After 24h free [3H]DNM was detectable in the urine
samples of animals given either free drug or sample 7
(Figure 9). Correspondingly little free [3H]DNM was
detected in the urine of animals given sample 8.
0 1 0 20 30 40 50 60
Fraction number
Figure 9 Sephadex G-25 elution of mouse urine collected 24h
after i.p. administration of (a) [3H]DNM; (b) sample 7; (c)
sample 8. Procedure is given in Materials and methods. Elution
of dextran blue (VX) and [3H]DNM is also shown.
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Table VI Body distribution of [3H]DNM and HPMA-[3H]DNM (samples 7 and 8) after i.p. administration
Timea
I h 5h 24h
Organ [3H]DNM Sample 7 Sample 8 [3H]DNM Sample 7 Sample 8 [3H]D,NM Sample 7 Sample 8
Liver 15.2 31.6 2.9 13.7 28.6 2.6 8.0 7.6 4.6
Lung 0.6 0.9 0.6 1.3 1.8 0.8 0.5 0.5 0.6
Kidney 2.6 6.5 1.9 8.3 8.5 2.3 14.2 3.8 1.0
Spleen 0.7 0.4 0.4 2.5 1.6 0.3 1.3 0.8 0.6
Heart 0.5 0.5 0.4 0.8 0.4 0.5 0.5 0.5 0.5
Stomach 4.8 1.9 1.2 2.8 5.6 1.2 3.3 0.9 0.5
Intestine 48.6 14.4 6.9 43.1 23.0 6.6 18.7 8.5 8.9
Peritoneal washings 22.1 28.1 63.2 5.6 9.9 3.7 1.9 0.7 1.3
Urine _b _ _ 11.4 1.8 48.3 11.4 40.9 60.0
Faeces - - - 6.2 16.9 14.8 34.7 30.6 12.7
Blood 5.0 15.9 22.5 4.3 1.8 18.9 6.0 5.2 9.3
Radioactivity recovered
as a percentage of
dose administered 48 52 50 26 29 43 22 41 48
aThe radioactivity recovered in each organ is expressed as a percentage of the total radioactivity recovered from the animal.
Recovery in respect of dose administered is also shown; bValues not determined.
Table VII Sephadex G-25 chromatography of urine and peritoneal
washings after administration of [3H]DNM, sample 7 or sample 8
Percentage ofradioactivity
([3H]) recoveredfrom
Length of the columna
Sample experiment
administered (h) Peak I Peak 2
Peritoneal washings
[3H]DNM 1 28.3 63.9
5 1.8 98.2
Sample 7 1 81.6 18.4
5 _b
Sample 8 1 98.4 156
Urine 5 - _
[3H]DNM 5 6.4 93.6
24 16.1 83.9
Sample 7 5
24 -
Sample 8 5 98.3 NDC
24 70.2 28.4
aRadioactivity eluting in peak 1 (Void volume) and a second peak
of lower molecular weight material expressed as a percentage of the
total radioactivity eluting from the column, see Figure 9; bThese
values were not determined; cNot detectable.
Discussion
Modification of anthracycline antibiotic disposition with the
aid of drug-carriers can produce an increase in a drug's
therapeutic index, and in certain cases overcome cell
resistance (Yanovich et al., 1984). This has been demon-
strated with anthracyclines using a number of different
carriers, including liposomes (Fichtler et al., 1984), low
density lipoprotein (Yanovich et al., 1984), and DNA or
protein carriers (Trouet & Jolles, 1984). In this study we
have shown that a soluble synthetic polymer may also have
potential as a carrier of anticancer agents. Administration of
DNM bound to HPMA copolymer, via a lysosomally
degradable tetrapeptide (Gly-Phe-Leu-Gly), increased the
mean survival-time (relative to untreated controls) of DBA2
mice bearing L1210 leukaemia and also produced a number
of animals surviving long-term (Figure 3 and Tables III &
IV). These data are in accord with previous studies
describing successful treatment of i.p. tumours using i.p.
administration of degradable drug conjugates: non-covalently
linked DNA (Deprez-de Campeneere & Trouet, 1980), poly-
L-aspartic acid and poly-L-lysine (Zunino et al., 1984), poly-
L-aspartic acid (Pratesi et al., 1985) and succinylated fetuin
or albumin (Trouet et al., 1982).
There are at least two mechanisms of action of macro-
molecular drug conjugates (Duncan, 1987). Conjugation of a
drug alters its pharmacokinetics and this simple procedure
can exclude drug from the principle sites of toxicity thus
improving the therapeutic index considerably. Secondly,
conjugation limits capture of drug to the cellular uptake
process of pinocytosis, affording potential to target to
particular cells using cell-specific surface receptors or
antigens to promote capture by receptor-mediated pino-
cytosis. Internalization of a drug-conjugate in this way
ultimately results in its exposure to lysosomal enzymes and
therefore lysosomally degradable conjugates can liberate
drug intracellularly following uptake. As yet there are no
convincing examples of significant, tumour-specific, drug
targeting, even with the use of tumour-specific monoclonal
antibodies as drug-carriers. Most drug conjugates currently
proposed probably exert their effect by modulation of the
body distribution, and rate of excretion, of the attached
agent.
Throughout this investigation sample 3, P-Gly-Gly-DNM,
shown previously (Kopecek & Duncan, 1987a) to be non-
biodegradable, was found to be completely inactive. In
contrast samples 4, 5 and 6, containing biodegradable drug-
carrier linkages, all displayed marked antitumour activity.
The stability of sample 8 was confirmed as almost all the
radioactivity recovered in the urine after i.p. administration
was macromolecular, i.e., polymer-bound[3H]DNM. In
contrast Sephadex G-25 chromatography of urine following
administration of sample 7 showed a large peak of low
molecular weight material coeluting with [3H]DNM. (Figure
9.) These observations suggest that drug release from HPMA
copolymer conjugates by enzymic hydrolysis is a prerequisite
for pharmacological activity. Inability of rat plasma and
serum to hydrolyse such HPMA copolymers (Rejmanova et
al., 1985); and the known ability of lysosomal enzymes to
cleave these substrates (Rejmanova et al., 1983; Duncan et
al., 1983) suggests that drug release occurs intracellularly.
Trouet et al. (1982) showed that albumin-DNM, and
albumin-Ala-Leu-DNM, were much less active against L1210
in vivo than albumin-Ala-Leu-Ala-Leu-DNM, an observation
that was attributed to resistance of the former to hydrolysis
by lysosomal enzymes. However, ability of anthracyclineACTIVITY OF HPMA-DAUNOMYCIN CONJUGATES IN VIVO 155
antibiotics to induce toxicity via interaction with the cell
surface should not be overlooked. Tokes et al. (1982) and
Tritton & Lee (1982) attached adriamycin to polyglutaral-
dehyde microspheres, and agarose respectively, and were
able to show that non-penetrating drug formulations can be
toxic to tumour cells in vitro, including L1210 leukaemia.
Previous in vitro studies with HPMA copolymer conjugates
(Duncan et al., 1987) showed differential toxicity of polymer
conjugates containing stable or biodegradable DNM-
polymer linkages to L1210 cells. The non-degradable
conjugates were slightly toxic, but much less so than
biodegradable ones, a factor attributed to cell-surface
activity. In these in vivo studies lack of activity of non-
degradable sample 3 implies that the observed antitumour
activity of biodegradable drug-conjugate is not simply caused
by cell surface interaction.
Inoculation of tumour intraperitoneally, followed by i.p.
treatment may apparently confine the tumour and treatment
to one body compartment, thus biasing the investigation in
favour of tumour targeting, or tumour killing. However,
polymer-DNM administered i.p. was also shown to be active
against s.c. implanted tumour (Table V) and the ability of
the polymeric conjugate to act at a site remote from the
point of administration is consistent with the short half-life
of radiolabelled HPMA copolymer-DNM conjugates in the
peritoneal cavity (Figures 6 & 7), demonstrated previously
(Seymour et al., 1987a), to be independent of polymer
molecular weight over the range 10,000-800,000.
HPMA copolymer-drug conjugates, either 125I-labelled or
containing [3H]DNM were eliminated from the body more
readily than [3H]DNM (Table VI; Figures 6 & 7). Taking
into account total recovery of radioactivity in respect of
administered dose, the rate of excretion of [3H]DNM was
more than three times greater when attached to polymer.
Attachment of DNM to polymer prevents random intra-
cellular access and therefore rapid binding of drug to
intracellular constituents such as DNA, and as the molecular
weight of the polymer conjugate is sufficiently small to pass
across the kidney glomerulus any conjugate resident in, or
passing into, the circulation was quickly removed. This may
in part explain the decreased toxicity of polymer-bound
drug. (Doses of polymer-bound drug up 20mgkg being
administered without any obvious ill effect.) The fact that
polymer-bound anthracyclines show less toxicity to human
lymphocytes and mouse spleen cells in vitro (R.ihovia,
unpublished) and are probably less cardiotoxic will also
contribute to the overall reduction in toxicity of conjugated
drug. It is noteworthy that the more rapid excretion of a
dose of polymer-drug is still accompanied by a measurable
therapeutic response.
The HPMA copolymer bearing [3H]DNM and galactos-
amine (sample 7) showed greater association with the liver
(Table VI) than polymer without the sugar, almost certainly
due to receptor-mediated pinocytic uptake by hepatocytes
(Ashwell & Harford, 1982; Duncan et al., 1986). DNM
subsequently released from this intracellular depot was
effective against L1210 inoculated i.p. (Table III). This is
perhaps surprising as the liver is known to be the primary
site of DNM metabolism (Craddock et al., 1973) and it
could be predicted that any DNM released from hepatocyte
lysosomes might be inactivated. This is clearly not the case
and these observations suggest that targeted HPMA co-
polymers bearing anthracyclines have potential, following i.v.
bolus administration, as a controlled release depot in the
liver. Anthracycline released could be used to treat primary
(known also to retain the galactose-recognising receptor,
Schwartz et al., 1982) and secondary liver cancer. Two lethal
diseases. HPMA copolymer-DNM conjugates administered
i.v. to mice were not non-specifically hepatotoxic as
measured by mouse weight and their plasma
transaminase/alkaline phosphatase levels (McCormick et al.,
1987).
Substitution of conjugates with the other carbohydrate
residue fucosylamine, did not increase the mean survival of
animals in comparison with treatment using non-
carbohydrate conjugate (Table IV), the only exception being
after administration of single doses (7.5mgkg-1) on day 3.
The explanation of this observation is not clear, but could
indicate greater expression of the fucose receptor during the
rapid growth phase of the developing ascites.
Recent experiments have shown that HPMA copolymer-
adriamycin conjugates are more effective than the described
DNM conjugates in prolonging life of DBA2 mice inoculated
with L1210 cells (Kopecek & Duncan, 1987b). After i.v.
administration they do not manifest toxicity until a dose of
75mgkg-1. As this anthracycline is one of the most
important clinical agents, such HPMA copolymer conjugates
appears to have real therapeutic potential. Unlike many of
the other drug-carriers evaluated in this context this polymer
and its conjugates are not immunogenic (1iAhova et al., 1984)
and so can be administered repeatedly. Use of techniques in
polymer chemistry to synthesize drug conjugates prevents
either denaturation of the carrier or inactivation of drug.
We thank the Cancer Research Campaign for funding this work and
The Royal Society and British Council for supporting the
international collaboration.
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